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Background: This study investigated the prognostic role of nuclear expression of p65 in patients with locally
advanced squamous cell carcinoma of the head and neck (SCCHN) receiving post-operative radio(chemo)
therapy.
Methods: Nuclear p65-expression (H-score ≤50 versus >50) plus twelve characteristics were analyzed in 151 patients
for overall survival (OS), metastases-free survival (MFS) and loco-regional control (LRC). Additional characteristics
included age, gender, Karnofsky performance score (KPS), pre-radiotherapy hemoglobin levels, tumor site, histological
grading, human papilloma virus (HPV)-status, T-classification, N-classification, American Joint Committee on Cancer
(AJCC)-stage, extent of resection and concurrent chemotherapy. Univariate analyses were performed with Kaplan-Meier
method and log-rank test, multivariate analyses with Cox proportional hazards model.
Results: On univariate analyses, p65-expression had a significant impact on OS (p < 0.001) and LRC (p < 0.001) but not
on MFS (p = 0.29). On multivariate analysis, KPS ≥80 (risk ratio [RR] 2.23; p = 0.012), HPV-positivity (RR 5.83; p = 0.020),
T1-T2 (RR 1.38; p = 0.048), N0-N2a (RR 2.72; p = 0.005) and complete resection (RR 2.02; p = 0.049) were positively
associated with OS; p65-negativity achieved borderline significance (RR 3.02; p = 0.052). Better MFS was associated
with KPS ≥80 (RR 2.49; p = 0.015), T1-T2 (RR: 1.74; p = 0.005), N0-N2a (RR: 6.22; p < 0.001) and complete resection
(RR 3.43; p = 0.003). Positive associations with LRC were found for p65-negativity (RR 5.06; p = 0.008), T1-T2
(RR: 1.49; p = 0.022), N0-N2a (RR: 2.97; p = 0.004) and favorable tumor site (RR 1.28; p = 0.025).
Conclusions: P65-negativity was significantly associated with improved LRC and achieved borderline significance
with respect to improved OS. Thus, p65-expression may be an additional target for novel agents in the treatment
of locally advanced SCCHN.
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Figure 1 Non-keratinizing carcinoma with immunostaining for
p65: Brown staining of 30% nuclei in moderate intensity,
original magnification 100x at microscope, bar = 100 μm.
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Many patients with squamous cell carcinoma of the
head and neck (SCCHN) present with locally advanced
disease, which is often associated with unsatisfactory
outcomes despite innovative treatment approaches [1-3].
Personalization of cancer treatment has become more
popular during recent years and may provide beneficial
effects also for the treatment of locally advanced
SCCHN. The knowledge of significant prognostic fac-
tors, which characterize a cancer patient’s individual
situation as precisely as possible, is important for indi-
vidualized therapies. Several clinical and pre-clinical pre-
dictors have been identified for patients with locally
advanced SCCHN [4-7]. Recently, the prognostic role of
nuclear factor kappa B (NF-ĸB) has been suggested in a
retrospective study of 101 SCCHN patients treated with
definitive radio-chemotherapy [8]. In that study based
on material from biopsies, nuclear expression of p65
(RelA), a transcription factor belonging to the NF-ĸB fam-
ily, was associated with worse overall survival (OS) and
metastases-free survival (MFS) in addition to a trend to-
wards worse loco-regional control (LRC). In addition,
Nakayama et al. found in their series of 36 untreated bi-
opsy specimens from patients with SCC and 15 specimens
with epithelial dysplasia of the oral cavity that high expres-
sion of p65 was associated with malignant behavior [9].
In several countries worldwide, the majority of patients
with locally advanced SCCHN are treated with surgical re-
section of the primary tumor plus neck dissection followed
by radiotherapy or, in case of specific risk factors, radio-
chemotherapy instead of definitive radio-chemotherapy.
Therefore, it would be important to know whether p65
(RelA) is also a significant predictor of treatment outcomes
after adjuvant radio(chemo)therapy of locally advanced
SCCHN. We feel that resected specimens provide more
histologic material for successful staining than biopsies.
Furthermore, in the previous clinical study, the human
papilloma virus (HPV)-status and the hemoglobin levels
prior to irradiation were not evaluated. Therefore, the
current study was initiated. It investigated the potential
prognostic role of p65 (RelA) in 151 patients treated with
resection followed by radio(chemo)therapy for non-
metastatic stage III/IV SCCHN.
Methods
Immunohistochemistry for p65 (RelA)
Nuclear expression of p65 (RelA) was analyzed in resected
tumor specimens of 151 patients who had received ob-
tained post-operative radiotherapy or radio-chemotherapy
for locally advanced SCCHN. The study was approved by
the local ethics committee (University of Lübeck). The pa-
tients have given written informed consent for the use of
their data within retrospective studies in general. Children
were not included in this study. Formalin-fixed andparaffin-embedded cancer tissues were sampled in a tissue
micro array with cores of 2.0 mm (Manual Tissue Arrayer
1, Beecher Instruments, Silver Spring, MD, USA). Histo-
logical sections of 4 μm were de-paraffinized in xylene
and rehydrated in graded alcohols. Antigene retrieval was
processed according to standard operating procedure for
our department of surgical pathology. Using 0.01 M citric
acid pH6.0 for 5 min in a microwave at 850 W showed
best results. Incubation with the primary antibody was
done for 120 minutes in a dilution of 1:70. In a previous
work by Balermpas et al., the polyclonal antibody ab31481
by Abcam plc, CB4 0FL Cambridge, UK) was used, but
was not available anymore, when our study was performed
[8]. After monoclonal antibody NF-kB p65 (clone L8F6) of
Cell Signaling Technology Inc. (#6956) did not show any
positive reaction, finally polyclonal rabbit Anti-NF-kB p65
antibody ab16502 (Abcam plc, CB4 0FL Cambridge, UK)
was used. Visualization was performed with biotin-free
poly-horseradish peroxidase-anti-mouse/rabbit/rat-IgG-
kit (ImmunoLogic BV, 6921 VB Duiven, Netherlands).
A diffuse large B-cell lymphoma served as positive con-
trol, and staining without primary antibody served as
negative control. For differentiation between p65-negative
and p65-positive tumors, the H-score was used [10]. The
H-score was obtained as follows: % cells with weak stain-
ing × 1 plus % cells with moderate staining × 2 plus %
cells with strong staining × 3. Tumors with an H-score
of ≤50 were considered p65-negative and those tumors
with an H-score of >50 were considered p65-positive.
Microscopic evaluation was carried out by an experienced
surgical pathologist, who was blinded to clinical and la-
boratory data. An example of a p65-positive tumor is
given in Figure 1.
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A total of 151 patients who had received surgery and
postoperative radiotherapy or radio-chemotherapy for
locally advanced SCCHN between 2000 and 2009 were
included in this retrospective study. Further inclusion
criteria were successful staining for p65, histologically
proven SCC of the oropharynx, oral cavity, hypopharynx
or larynx, and stage III or IV disease. Surgery was per-
formed as resection of the primary tumor plus modified
radical neck dissections. Conventionally fractionated
radiotherapy (5 × 2 Gy per week) began 4–5 weeks after
surgery. The PTV 1 included the primary tumor plus
the bilateral cervical and supraclavicular lymph nodes
(50–60 Gy). The PTV 2 included the primary tumor
plus the involved lymph nodes; total doses were 60 Gy
after complete resection and 66–70 Gy after incomplete
resection. Lymph node levels with extra-capsular spread
(ECS) received a total dose of 66 Gy. In case of incom-
plete resection and/or ECS, concurrent chemotherapy
with 20 mg/m2 of cisplatin on days 1–5 and 29–33 plus/
minus 600/1000 mg/m2 of 5-fluorouracil on days 1–5
and 29–33 was administered.
Additional potential prognostic factors
Twelve variables were investigated in addition to nuclear
expression of p65 (RelA) for associations with loco-
regional control (LRC), metastases-free survival (MFS)
and overall survival (OS). These twelve variables were
age (≤60 years vs. ≥61 years), gender, Karnofsky per-
formance score (KPS ≤70 vs. KPS ≥80), hemoglobin
levels prior to irradiation (<12 g/dl vs. ≥12 g/dl), tumor
site (oropharynx vs. hypopharynx vs. larynx vs. oral cav-
ity/floor of mouth), histologic grade (G1-2 vs. G3), HPV-
status of the tumor (negative vs. positive; HPV-positivity
was defined as presence of both a specific p16-pattern and
a positive in-situ hybridization-result.), T-classification
(T1-T2 vs. T3-T4), N-classification (N0-N2a vs. N2b-N3),
American Joint Committee on Cancer (AJCC) stage (stage
III vs. stage IV) extent of resection (complete vs. incom-
plete) and administration of concurrent chemotherapy (no
vs. yes). The distribution of these variables is given in
Table 1.
HPV-status
Formalin-fixed, paraffin-embedded tumor probes were
analyzed for DNA of HPV-high-risk subtypes 16, 18, 31,
33 and 51 with in-situ-hybridization marked with anti-
biotin-antibody processed in an autostainer. The mor-
phologic criteria of positive hybridization-signals were
adapted to the well-known morphology of CISH for
other genes [11]. P16-immunoreactivity was qualitatively
analyzed in accordance with morphologic criteria of in-
tense confluent nuclear and cytoplasmic staining of tumor
cells (positive). A tumor was defined as HPV-positive, if it









Negative 90 71 68
Positive 71 n.a. n.a. <0.001
Age
≤ 60 years 89 68 66
≥ 61 years 89 70 66 0.92
Gender
Female 91 84 78
Male 88 64 62 0.19
Karnofsky performance score
≤ 70 88 57 49
≥ 80 90 76 76 0.012
Hemoglobin level pre-RT
< 12 g/dl 83 46 46
≥ 12 g/dl 92 78 74 0.002
Tumor Site




Hypopharynx 77 56 56
Larynx 89 75 75 0.35
Histologic grade
G1-2 95 73 69
G3 85 65 63 0.26
HPV status
Negative 87 65 62
Positive 100 93 93 0.023
T-classification
T1-T2 94 82 77
T3-T4 84 56 56 0.009
N-classification
N0-N2a 96 81 81
N2b-N3 85 61 57 0.024
AJCC stage
Stage III 98 82 82
Stage IV 85 62 58 0.025
Extent of resection
Complete 91 73 70
Incomplete 82 50 50 0.017
Chemotherapy
No 88 69 67
Yes 90 68 65 0.99
n.a. = not available; significant p-values are given in bold.
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of oncogene activity of E6- and E7-gene and a positive
in-situ hybridization-result. Positive control was a squa-
mous-type carcinoma-in-situ of the cervix uteri of a pa-
tient with known HPV-subtype (HPV-Chip Type 3.5C,
Chipron GmbH, Berlin, Germany). As negative control
tumor tissue were stained with anti-biotin antibody only
and cancer without p16-immunoreactivity and without
amplification of HPV-high-risk-DNA in PCR with LCD-
Array HPV-Chip 3.5 [12].
By chromogene in-situ-hybridization, we could identify
DNA of human papilloma-virus high-risk subtypes 16,
18, 31, 33 and 51 in one assay but could not discrimin-
ate, which of the five subtypes was involved. In another
assay we tested for low risk subtypes 6 and 11, but did
not found them in carcinoma. If cases were positive for
p16 in a cluster, which is typical for oncogene activation of
HPV, but negative in chromogene in-situ-hybridization,
we postulated another HPV-subtype than 16, 18, 31, 33 or
51 or a low sensitivity in paraffin embedded tissue, which
was stored for years in an archive at room temperature.
Statistical considerations
LRC, MFS and OS were referenced from the last day of
radiotherapy/radio-chemotherapy. Univariate analyses
were performed with the Kaplan-Meier method and the
log-rank test. Those variables showing a significant or
borderline significant (p ≤ 0.05) association with treat-
ment outcomes on univariate analyses were also in-
cluded in a multivariate analysis performed with the Cox
proportional hazards model. If T-classification or N-
classification and AJCC stage were significant in the uni-
variate analysis, AJCC-stage was not included in the
multivariate analysis, as it is a confounding variable of
both T-classification and N-classification.
Results
The median follow up was 21 months (range 0–
67 months) in the entire cohort and 24 months (6–
66 months) in those patients alive at the last follow up.
Of those 19 patients with an HPV-positive tumor, 17 pa-
tients had oropharynx cancer, one patient larynx cancer
and one patient cancer of the oral cavity.
On the univariate analysis of OS (Table 2), p65-
negativity (Figure 1, p < 0.001), KPS ≥80 (p = 0.012), pre-
radio(chemo)therapy hemoglobin levels of ≥12 g/dl (p =
0.002), HPV-positivity (p = 0.023), T-classification 1–2
(p = 0.009), N-classification 0-2a (p = 0.024), AJCC-stage
III (p = 0.025) and complete resection (p = 0.017) were
positively associated with survival. In the subsequent
multivariate analysis (performed without AJCC-stage),
KPS (risk ratio [RR] 2.36; 95%-confidence interval [CI]
1.26-4.48; p = 0.007), HPV-status (RR 5.51; 95%-CI 1.17-
100.00; p = 0.027), T-classification (RR 1.39; 95%-CI









Negative 87 79 76
Positive 86 n.a. n.a. 0.29
Age
≤ 60 years 89 77 74
≥ 61 years 85 82 76 0.90
Gender
Female 91 84 77
Male 86 77 75 0.41
Karnofsky performance score
≤ 70 82 72 63
≥ 80 91 83 81 0.049
Hemoglobin level pre-RT
< 12 g/dl 83 75 75
≥ 12 g/dl 89 80 75 0.79
Tumor Site




Hypopharynx 72 55 55
Larynx 91 87 79 0.036
Histologic grade
G1-2 86 78 73
G3 88 79 76 0.90
HPV status
Negative 87 76 72
Positive 95 95 95 0.09
T-classification
T1-T2 95 88 85
T3-T4 80 71 65 0.013
Rades et al. BMC Cancer  (2015) 15:102 Page 5 of 81.01-1.94; p = 0.041) and N-classification (RR 2.63; 95%-
CI 1.29-5.90; p = 0.007) maintained significance. P65-
expression achieved borderline significance (RR 3.02;
95%-CI 0.99-7.60; p = 0.052). Hemoglobin levels showed
a trend (RR 1.76; 95%-CI 0.94-3.26; p = 0.08), and extent
of resection was not significant (RR 1.81; 95%-CI 0.88-
3.52; p = 0.11).
On univariate analyses of MFS (Table 3), a positive im-
pact was found for KPS ≥80 (p = 0.049), favorable tumor
site (oropharynx or larynx cancer; p = 0.036), T-
classification 1–2 (p = 0.013), N-classification 0-2a (p =
0.004), AJCC-stage III (p = 0.011) and complete resection
(p = 0.002). HPV-positivity showed a trend towards im-
proved MFS (p = 0.09). P65-expression was not signifi-
cantly associated with MFS (Figure 2, p = 0.29). In the
corresponding multivariate analysis (performed without
AJCC-stage), KPS (RR 2.49; 95%-CI 1.19-5.29; p = 0.015),
T-classification (RR: 1.74; 95%-CI: 1.18-2.64; p = 0.005),
N-classification (RR: 6.22; 95%-CI: 2.34-21.56; p < 0.001)
and extent of resection (RR 3.43; 95%-CI 1.54-7.34; p =
0.003) were significant; tumor site (RR: 1.13; 95%-CI:
0.88-1.43; p = 0.34) was not significant.
The univariate analysis of LRC (Table 4) revealed posi-
tive associations with LRC for p65-negativity (Figure 2,
p < 0.001), pre-radio(chemo)therapy hemoglobin levels
of ≥12 g/dl (p = 0.037), HPV-positivity (p = 0.041), T-
classification 1–2 (p = 0.007), N-classification 0-2a (p =
0.040) and AJCC-stage III (p = 0.042). Favorable tumor
sites achieved borderline significance (p = 0.050). In the
multivariate analysis (performed without AJCC-stage),
p65-expression (RR 5.06; 95%-CI 1.63-13.24; p = 0.008),
T-classification (RR: 1.45; 95%-CI: 1.03-2.09; p = 0.033),
N-classification (RR: 2.83; 95%-CI: 1.31-6.81; p = 0.007)
and tumor site (RR 1.36; 95%-CI 1.09-1.71; p = 0.008)
remained significant. Hemoglobin levels (RR 1.64; 95%-
CI 0.82-3.17; p = 0.16) and HPV-stage (RR 2.49; 95%-CI
0.49-45.45; p = 0.32) were not significantly associated
with LRC.N-classification
N0-N2a 96 90 90
N2b-N3 82 72 67 0.004
AJCC stage
Stage III 95 89 89
Stage IV 83 73 68 0.011
Extent of resection
Complete 90 84 80
Incomplete 74 57 57 0.002
Chemotherapy
No 88 86 82
Yes 86 71 68 0.16
n.a. = not available; significant p-values are given in bold.Discussion
The outcomes after treatment of patients with locally
advanced SCCHN need to be improved. In recent years,
promising new molecular targeted therapies have been
introduced for these patients including epidermal
growth factor receptor monoclonal antibodies, tyrosine
kinase inhibitors, vascular endothelial growth factor re-
ceptor inhibitors, and inhibitors of other pathways and
targets [13]. Furthermore, modern radiation techniques
have been more widely used for the treatment of
SCCHN including intensity-modulated radiotherapy,
adaptive intensity-modulated radiotherapy and proton
therapy, either alone or in combination with systemic
agents [14-16].
Figure 2 Impact of p65-expression on overall survival (top),
metastases-free survival (middle) and loco-regional
control (bottom).









Negative 88 76 72
Positive 43 n.a. n.a. <0.001
Age
≤ 60 years 83 70 67
≥ 61 years 90 79 75 0.23
Gender
Female 91 78 78
Male 84 71 67 0.31
Karnofsky performance score
≤ 70 83 69 64
≥ 80 88 77 74 0.19
Hemoglobin level pre-RT
< 12 g/dl 79 60 60
≥ 12 g/dl 89 78 73 0.037
Tumor Site




Hypopharynx 82 71 71
Larynx 87 77 69 0.050
Histologic grade
G1-2 91 78 74
G3 82 70 67 0.24
HPV status
Negative 84 69 65
Positive 94 94 94 0.041
T-classification
T1-T2 92 83 77
T3-T4 80 64 64 0.007
N-classification
N0-N2a 90 82 82
N2b-N3 83 68 63 0.040
AJCC stage
Stage III 91 82 82
Stage IV 83 68 63 0.042
Extent of resection
Complete 88 75 71
Incomplete 78 67 67 0.46
Chemotherapy
No 87 77 70
Yes 85 69 69 0.99
n.a. = not available; significant p-values are given in bold.
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expression of NF-ĸB to be a new marker for decreased
radio-sensitivity in patients irradiated for early-stage
cancer of the larynx [17]. The study matched 35 patients
with a local recurrence to 70 patients without a recur-
rent tumor. NF-ĸB was significantly associated with local
Rades et al. BMC Cancer  (2015) 15:102 Page 7 of 8failure in both the univariate (p = 0.008) and the multi-
variate (p = 0.04) analysis. In recurrent cancers, expres-
sion of NF-ĸB was markedly increased in 80% (23 of 29)
of tumors. In 2013, another retrospective study of 77 pa-
tients receiving radiotherapy or radio-chemotherapy for
SCCHN with a relatively favorable prognosis (64% T1-2,
70% N0, 48% AJCC-stage I-II) was reported [18]. Local
control at 5 years was significantly better with low ex-
pression of NF-ĸB than with higher expression of NF-ĸB
(80% vs. 42%, p = 0.001). Also this study suggested a cor-
relation between high levels of expression of NF-ĸB and
decreased radio(chemo)-sensitivity. These data were sup-
ported by another retrospective study of 101 patients
treated with radio-chemotherapy for locally advanced
SCCHN [8]. Mean follow up time was 25 months (range
2.3-63 months). Patients with a p65-positive tumor had
a worse prognosis than those patients with a p65-
negative tumor. The two-year OS rates were 40% and
67%, respectively (p = 0.008), the 2-year MFS rates 38%
and 62%, respectively (p = 0.008), and the 2-year LRC
rates 40% and 62%, respectively (p = 0.069). These three
retrospective studies were performed in patients treated
with definitive radiotherapy or radio-chemotherapy
[8,17,18]. In contrast, the present study was performed
in patients receiving radio(chemo)therapy in an adjuvant
setting following resection of the primary tumor plus
neck dissection. Furthermore, two of the previous stud-
ies were performed in SCCHN patients with a more fa-
vorable prognosis (48%-100% early stage tumors).
Therefore, the comparison of our study to the three pre-
vious studies has some limitations.
In accordance with the three previous studies
[8,17,18], our study also revealed a significant impact of
the nuclear expression of NF-ĸB (p65/RelA) on treat-
ment outcomes. The prognostic role of the nuclear ex-
pression of NF-ĸB (p65/RelA) may form the basis for
the development of new targeted therapies for locally ad-
vanced SCCHN. However, the retrospective design of
the four studies creates the risk of including inapparent
selection biases. We aimed to reduce the risk of such
biases by including only patients who had received re-
section plus neck dissection followed by radio(chemo)
therapy. The cancer specimens were from resection and
not from biopsy, which may have reduced a potential in-
fluence of the quality of staining for p65. In general,
staining will provide better results if it is performed in
larger resected specimens rather than in smaller speci-
mens from biopsies. However, these results of our study
and of the three previous reports from the literature
should ideally be confirmed prospective cohorts of pa-
tients with locally advanced SCCHN [8,17,18].
Improved treatment outcomes were also significantly as-
sociated with better performance status (KPS ≥80), favor-
able tumor site (oropharynx or larynx), HPV-positivity,lower tumor stage (T1-2, N0-2a, AJCC-stage III) and
complete resection in the present study. Hemoglobin
levels prior to radiotherapy of ≥12 g/dl showed a trend to-
wards better OS. These findings agree with the data from
the reported literature which reveals consistency of our re-
sults [19-23].
Conclusions
P65-negativity was significantly associated with im-
proved LRC and achieved borderline significance with
respect to improved OS. Thus, p65-expression may be
an additional target for novel agents in the treatment of
locally advanced SCCHN.
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